What we know is that $CODX was invited to ring the bell by NASDAQ because of their momentous accomplishments. We'll learn later in the day how $BAYRY is using $CODX's patented multiplex in $BAYRY applications, but we already know that $BAYRY was able to test for FIFTEEN targets in a single test using $CODX technology. These were targets that $BAYRY chose and the test will be cheaper and more efficient that a currently marketed test that only has a SINGLE target. There may not be any sales news tomorrow, but it is coming soon as details emerge. $BAYRY isn't involved for charity or fun. Ag Bio is only a piece of the pie... The new disease diagnostic sales became possible close to December last year. The disease vertical offers multiplex tests that are cheaper than single target tests and examine some of the most prevalent diseases in the world. *Don't forget that Cancer is being targeted as well. Can you imagine getting a liquid biopsy multiplex instead of an incision biopsy?